ArticleAnnals of surgical oncology2026
Recent National Trends in Time to Breast Cancer Surgery Before and After the COVID-19 Pandemic Onset and Predictors of Failure to Receive Timely Surgery.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTime to surgery (TTS) for breast cancer has been increasing for decades, with delays associated with worse survival. A 2022 Commission on Cancer (CoC) quality measure requires upfront surgery within 60 days after diagnosis (BCSdx). The long-term effects of the COVID-19 pandemic on TTS and compliance with BCSdx are unknown.
methodsUsing the National Cancer Database, the study identified 520,967 women with a diagnosis of clinical stages I to III invasive breast cancer from 2014 to 2023 who underwent upfront surgery. Time to surgery was defined as days from diagnosis to definitive surgery. Diagnosis year was modeled continuously and categorically (pre-pandemic 2014-2019, pandemic onset 2020, post-pandemic onset 2021-2023). Linear and logistic regression were used to identify factors associated with TTS and odds of not having surgery in ≤ 60 days.
resultsBetween 2014 and 2023, the mean TTS increased from 37 to 50 days (+ 13 days). Compared with 2014-2019, the 2021-2023 period was associated with + 7.51 mean days (95% confidence interval [CI], 7.35-7.67 days) and 1.90 times (95% CI, 1.87-1.94 times) increased odds of not meeting BCSdx in the multivariable analysis. Longer TTS also was associated with immediate reconstruction (β = + 8.27 days), uninsured status (β = + 7.99 days), and diagnosis at another facility (β = + 6.55 days). The proportion of patients with a TTS of ≤ 60 days declined from 88% to 74%. The strongest predictors of noncompliance were uninsured status (odds ratio [OR], 2.10), diagnosis at another facility (OR, 1.81), immediate reconstruction (OR, 1.81), black race (OR, 1.72), and Hispanic ethnicity (OR, 1.70).
conclusionsThe increase in TTS for breast cancer accelerated after the onset of the COVID-19 pandemic, with a concomitant decrease in BCSdx compliance. Strategies to improve care coordination, particularly for at-risk populations, are needed to address this quality measure.
Identifiers
42897381What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.